COVID-19: Drugs in Development


The COVID-19 outbreak, which started in December 2019 in Wuhan City, China, was declared a "Public Health Emergency of International Concern" by the WHO on January 30, 2020. The outbreak was characterized as a pandemic on March 11, 2020.

Currently, there are no drugs to treat COVID-19, caused by the novel coronavirus SARS-CoV-2.

Listed below are companies that are in the race to find a treatment or vaccine for the novel coronavirus.

Subscribe to RTT Intelligent Investor for FREE 7-Day Trial with complete access to COVID-19 Drugs in Development Calendar.

Company Name
Current Stage
Next Milestone
Last Updated
Moderna, Inc
mRNA-1273 Vaccine
On Sept.21, 2021, initiated clinical study for a third dose of the vaccine in people with organ transplant.
On Sep.18, 2021, FDA Panel voted unanimously in favor of COMIRNATY booster for Emergency Use only in people 65 and older and certain high-risk populations but not for general population.
Eiger BioPharmaceuticals Inc.
The company said that the first patients were dosed in the Phase 3 study of Lambda, dubbed Together, in newly diagnosed, outpatients with COVID-19.

--On Sept. 20, 2021, Data Safety Monitoring Board recommended continuation of Phase 3 Together study.
Moderna, Inc
On Sept.20, 2021, received full approval for Covid-19 vaccine Spikevax in Canada.
Appili Therapeutics Inc.
On October 20, 2020, initiated Phase 2 study study dubbed Control, evaluating the effectiveness of favipiravir as a preventative measure against COVID-19 outbreaks in long-term care facilities in Canada.
--On Nov. 24, 2020, received clearance from Health Canada to begin Phase 3 study dubbed PEPCO in the prevention of COVID-19.
--On Dec.2, 2020, initiated Phase 3 study dubbed PRESECO in the U.S.
AB Science SA
Phase 2 study in Covid-19 treatment.
--On June 1, 2021, temporarily paused Phase 2 study, after identifying a potential risk of ischemic heart disease with masitinib.
--On July 12, 2021, the measures proposed by AB Science to reinforce patient safety in masitinib trials were accepted by French National Agency.
--On Sept. 16, 2021, received clearance from the Russian Health Ministry to resume patient enrollment in the phase 2 study.
CalciMedica Inc.
Phase 2 study in hospitalized patients with COVID-19 pneumonia (CARDEA)
Results reported from CARDEA on Sep.14, 2021, suggest that Auxora may rapidly reduce inflammation and reduce damage to vital organ tissue
RedHill Biopharma Ltd.
Global Phase 2/3 study of Opaganib in patients hospitalized with severe SARS-CoV-2 infection

-- On Jan.29, 2021, Data Safety Monitoring Board (DSMB) recommended that the study continue following a pre-scheduled futility review.
--On Sept. 14, 2021, topline data from the Phase 2/3 study of opaganib in hospitalized patients with severe COVID-19 pneumonia were reported, that did not meet primary endpoint.
Top-line data and potential global emergency use authorization applications are expected in the second quarter of 2021

Get Full Access to latest records of COVID-19 Drugs in Development Calendar by subscribing to RTT Intelligent Investor with FREE 7-Day Trial. (No Credit Card Required)

Editors Pick
Boeing expects Europe's commercial aviation fleet to need 8,705 new airplanes through 2040 to cater to the growing leisure travel market in the region and fleet replacements with more fuel-efficient models, according to the Boeing's 2021 Commercial Market Outlook (CMO), an annual forecast of long-term demand for commercial airplanes and services. The U.S. Food and Drug Administration authorized marketing of a software developed by Paige.AI, a provider of AI-based digital diagnostics, which could help pathologists to identify prostate cancer. The software, called Paige Prostate, is the first and only artificial intelligence or AI-based pathology product to receive FDA approval for in vitro diagnostic or IVD use in detecting cancer... General Mills (GIS) said its first-quarter top- and bottom-line results were ahead of its expectations. The company also reaffirmed its fiscal 2022 outlook. Looking forward, General Mills anticipates changes in consumer behaviors driven by the COVID-19 pandemic will result in ongoing elevated consumer...